Orion – 4 trial: Inclisiran effective in reducing cholesterol

Inclisiran is a popular drug, studied for its effect to control bad cholesterol or LDL levels in blood, a proprotein convertase subtilisin/kexin type synthesis inhibitor which has been found to reduce LDL-cholesterol by about 50-60%. High cholesterol is a serious health issue that needs to be managed immediately, several medications to prevent cholesterol levels in blood are presently available in market.

ORION-4 in ClinicalTrials.gov investigated the effects of inclisiran on major adverse cardiovascular events. Approximately 15,000 participants aged 55 years or older with pre-existing atherosclerotic cardiovascular disease were randomized between inclisiran sodium 300 mg and matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) in a 1:1 ratio for a planned median duration of about 5 years. So far inclisiran is effective in preventing heart attacks and strokes.